Trial Profile
ENDEAVOR-Safety
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2008
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Registrational
- Acronyms ENDEAVOR-Safety
- Sponsors Medtronic
- 20 Oct 2008 New trial record.